Category: Medicine
Pharmaceutical Executive: June 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in an interactive PDF format.
Imbruvica Demonstrates Long-Term Efficacy, Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
Data presented at the European Hematology Association Congress indicated that patients with chronic lymphocytic leukemia treated with Imbrivica had a significantly longer median progression-free survival [more…]
Movano Health Announces Addition of Deep Learning Software to AI-Powered Heart Rate Monitoring Software
According to the company, the additional software makes it algorithm more accurate.
Biopharma Leadership in Times of Transition
How pharma and biotech leaders can navigate today’s challenging landscape—focusing on revamped approaches in business operations, talent strategy and development, and more to meet the [more…]
AbbVie Presents New Data from Two Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO [more…]
Study Suggests Individuals Born Preterm Are More Likely to Have Lower Incomes in Adulthood
Investigators followed a group of people born from 1990-1996 to assess whether the association between preterm birth and income differs according to family socioeconomic status [more…]
Weight Loss Drug Shortage Prompts Multiple Companies to Launch Shortage Tracking Platforms
Hypermedica and Ro announced platforms to help patients find access to affordable weight loss medications.
The Healthcare System is Changing—So How Should We Respond?
What pharma needs to do to keep up with the rise in value-based care.
What Crucial Skill Sets are Global Biopharmas Asking Premier Executive Recruitment Firms to Search for in Top Talent?
A Q&A with Egon Zehnder’s Sergio Della Zassa about what biopharma executives and search firms are looking for in terms of table stakes skill sets [more…]
FDA Approves GSK’s Arexvy to Prevent Respiratory Syncytial Virus in Adults Aged 50-59 with Increased Risk
Arexvy receives expanded indication to include adults aged 59 years and younger to prevent RSV lower respiratory tract disease.